ZEAL — Zealand Pharma A/S Share News
0.000.00%
Last trade - 00:00- DKK16.22bn
- DKK2.17bn
- DKK9.21bn
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Zealand Pharma And OTR Therapeutics Enters Multi-Program Strategic Collaboration
Zealand Pharma to accelerate drug development for obesity, metabolic disease (updated)
Brief: Zealand Pharma, OTR Therapeutics Enter Strategic Collaboration
Zealand Pharma to accelerate drug development for obesity, metabolic disease
Zealand Pharma to accelerate drug development for obesity, metabolic disease
Brief: Zealand Pharma Outlines Metabolic Frontier 2030 Strategy
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Amycretin trial results lift Novo shares
Zealand Pharma pauses development of obesity drug candidate (updated)
Zealand Pharma scraps obesity drug candidate, citing crowded market, Bloomberg News reports
Brief: Zealand Scraps Potential Obesity Drug, Citing Crowded Market - Bloomberg News
Brief: Zealand Pharma Q3 Operating Loss DKK 461.3 Million
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Pharma companies announce direct-to-consumer sales and price cuts in US
Zealand Pharma slumps, analysts point to rival trial data
Lilly moves obesity drug to late-stage trials after it shows promise (updated)
Factbox: Who's on Novo Nordisk's board after major shakeup?